OrthoPediatrics Corp. (NASDAQ:KIDS) Shares Sold by Quantbot Technologies LP

Quantbot Technologies LP lowered its holdings in OrthoPediatrics Corp. (NASDAQ:KIDS) by 80.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,106 shares of the company’s stock after selling 4,667 shares during the quarter. Quantbot Technologies LP’s holdings in OrthoPediatrics were worth $26,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in KIDS. HighTower Advisors LLC purchased a new position in OrthoPediatrics in the 4th quarter valued at approximately $268,000. Charles Schwab Investment Management Inc. increased its position in shares of OrthoPediatrics by 2.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 136,234 shares of the company’s stock valued at $3,158,000 after buying an additional 3,800 shares in the last quarter. Mutual of America Capital Management LLC raised its stake in shares of OrthoPediatrics by 57.1% during the 4th quarter. Mutual of America Capital Management LLC now owns 169,021 shares of the company’s stock worth $3,918,000 after buying an additional 61,412 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of OrthoPediatrics by 3.8% during the 4th quarter. Bank of New York Mellon Corp now owns 57,710 shares of the company’s stock worth $1,338,000 after buying an additional 2,099 shares during the last quarter. Finally, AlphaCentric Advisors LLC purchased a new stake in shares of OrthoPediatrics in the 4th quarter worth about $171,000. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

OrthoPediatrics Stock Up 1.7 %

NASDAQ:KIDS opened at $25.05 on Wednesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17. The company has a market capitalization of $608.39 million, a price-to-earnings ratio of -20.37 and a beta of 1.22. OrthoPediatrics Corp. has a one year low of $21.02 and a one year high of $35.99. The stock has a 50-day simple moving average of $24.70 and a 200 day simple moving average of $25.16.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The business had revenue of $52.67 million during the quarter, compared to the consensus estimate of $51.16 million. During the same period in the previous year, the business earned ($0.23) EPS. Sell-side analysts predict that OrthoPediatrics Corp. will post -0.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

KIDS has been the subject of a number of analyst reports. Truist Financial cut their price target on OrthoPediatrics from $28.00 to $25.00 and set a “hold” rating for the company in a report on Wednesday, December 18th. Stifel Nicolaus cut their price objective on shares of OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, March 5th. Finally, Needham & Company LLC reissued a “buy” rating and set a $42.00 price objective on shares of OrthoPediatrics in a research note on Wednesday, March 5th.

Insiders Place Their Bets

In other OrthoPediatrics news, CFO Fred Hite sold 6,443 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $160,172.98. Following the completion of the transaction, the chief financial officer now directly owns 207,989 shares in the company, valued at $5,170,606.54. This trade represents a 3.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, General Counsel Daniel J. Gerritzen sold 5,310 shares of the business’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $132,006.60. Following the sale, the general counsel now directly owns 110,767 shares in the company, valued at approximately $2,753,667.62. This trade represents a 4.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 23,732 shares of company stock worth $589,978. 31.80% of the stock is owned by company insiders.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.